
    
      This is a study of a drug known as LY2127399, which will be given with a common treatment for
      multiple myeloma called bortezomib (Velcade). The primary purpose of this study is to
      (1)Determine the safety of LY2127399 in combination with bortezomib and any side effects that
      might be associated with it; (2)Assess whether LY2127399 in combination with bortezomib may
      help patients with relapsed or refractory multiple myeloma; (3)How much LY2127399 should be
      given to patients along with bortezomib.
    
  